Search results
Is the FDA Pausing More Cancer Trials? It's Hard to Tell
Medscape· 2 weeks agoIs the FDA Pressing Pause on More Cancer Trials? In October, the US Food and Drug Administration (...
HOOKIPA advances HPV cancer trial with FDA nod By Investing.com
Investing.com· 1 week ago(NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has announced the final design for its ...
Earnings call: Viking Therapeutics reports positive Phase 2 results By Investing.com
Investing.com· 1 week agoViking Therapeutics (NASDAQ:VKTX) has announced encouraging results from its Phase 2 VENTURE study...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with...
WKBN 27 Youngstown· 3 days agoFood and Drug Administration (FDA) has completed its 30-day review of the investigational new drug (IND) application for the use of bremelanotide, a...agonist ...
Center for Clinical Trial Innovation furthers FDA’s diversity goals, rare disease drug development -...
JD Supra· 2 weeks agoThe C3TI demonstration program is an excellent opportunity for pharmaceutical and biotechnology companies to closely interact with FDA and</ ...
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at...
CBS 47 Fresno· 1 week ago...University of Houston College of Pharmacy, and the Principal Investigator for microbiology and microbiome aspects of the ibezapolstat clinical trial program and Acurx Scientific Advisory Board member will give an oral presentation entitled: A Phase 2, Randomized, Double-Blind Study of...
...PEDIATRIC BRAIN CANCER, ANNOUNCES FDA APPROVAL OF TOVORAFENIB (DAY101... SCIENTIFIC CONSORTIUMAND...
FOX 4 Kansas City· 2 weeks agoThis approval is a direct result of the pivotal Phase 2 FIREFLY-1 trial/PNOC026, which demonstrated...
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Motley Fool via Yahoo Finance· 2 hours agoThe medicine also had a reasonable safety profile. Here's some even better news: The U.S. Food and...
Ellipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2
NBC 17 Raleigh· 4 days agoFood and Drug Administration (FDA) has confirmed the company's next generation selective RET inhibitor (SRI), EP0031/A400, is clear to progress into < ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 1 week agoPhase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment ...